FGF23 and coronary artery disorder: Our mRNA findings also support involvement of fibroblast growth factor 23 (FGF23) in CAD, which is expressed in the heart, promotes hypertrophy and remodelling and has been identified as an independent marker for cardiovascular risk in patients with dilated cardiomyopathy, ischaemic heart disease, acute decompensated and chronic HF [50,51,52,53,54], along with stromal antigen 2 (STAG2), which is required for proliferation and regulation of cardiac transcriptional programs [55].